ADC ID	DRG0DNWSM
ADC Name	ABT-700 (S238C)-PBD
Synonyms	ABT-700 (S238C)-PBD; ABT-700-PBD; ABT 700-PBD; ABT 700 PBD; ABT700 PBD    Click to Show/Hide
Organization	AbbVie, Inc.
Drug Status	Investigative
Indication	In total 3 Indication(s) Non-small cell lung cancer [ICD11:2C25] Investigative Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z] Investigative Squamous cell cancer [ICD11:2D60-2D61] Investigative
Drug-to-Antibody Ratio	2
Structure
	3D MOL			2D MOL
Antibody Name	Telisotuzumab					Antibody Info
Antigen Name	Hepatocyte growth factor receptor (MET)					Antigen Info
Payload Name	PBD dimer					Payload Info
Therapeutic Target	Human Deoxyribonucleic acid (hDNA)					Target Info
Linker Name	Mc-Val-Ala					Linker Info
Conjugate Type	Random conjugation through reduced inter-chain cysteines.
Combination Type	VaPBD

Standard Type	Value	Units	Animal Model (No. of PDX)
Tumor Growth Inhibition value (TGI)	70.68	%	Non-small cell lung cancer PDX model (PDX: CTG-0363)
Tumor Growth Inhibition value (TGI)	75.79	%	Non-small cell lung cancer PDX model (PDX: CTG-0170)
Tumor Growth Inhibition value (TGI)	88.94	%	Non-small cell lung cancer PDX model (PDX: CTG-0159)

Standard Type	Value	Units	Cell Line	Disease Model
Tumor Growth Inhibition value (TGI)	92.94	%	SW48 cells	Colon adenocarcinoma

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	1	pM	SK-CO-1 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	1	pM	LS174T cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	< 1	pM	U-138MG cells	Astrocytoma
Half Maximal Inhibitory Concentration (IC50)	< 1	pM	M059J cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	< 1	pM	M059K cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	< 1	pM	DBTRG-05MG cells	Anaplastic astrocytoma
Half Maximal Inhibitory Concentration (IC50)	2.9	pM	SW48 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	3	pM	HCC15 cells	Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	4	pM	DLD-1 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	4	pM	HT-29 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	5	pM	HCT 116 cells	Colon carcinoma
Half Maximal Inhibitory Concentration (IC50)	5	pM	SW620 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	5	pM	SF264 cells	Gliosarcoma
Half Maximal Inhibitory Concentration (IC50)	6	pM	SW403 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	6	pM	SNB-19 cells	Astrocytoma
Half Maximal Inhibitory Concentration (IC50)	7	pM	COLO 201 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	< 7	pM	U-251MG cells	Astrocytoma
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	NCI-H441 cells	Lung papillary adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	RKO cells	Colon carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	SW1463 cells	Rectal adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.01	nM	WiDr cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	Hs 746.T cells	Gastric adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	M059J cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	KP-4 cells	Pancreatic carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	NCI-H820 cells	Lung papillary adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	SW900 cells	Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	COLO 205 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.02	nM	COLO 320DM cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.03	nM	SW1116 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.04	nM	NCI-H226 cells	Pleural epithelioid mesothelioma
Half Maximal Inhibitory Concentration (IC50)	0.04	nM	LS1034 cells	Cecum adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.04	nM	COLO 320HSR cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.04	nM	SF539 cells	Gliosarcoma
Half Maximal Inhibitory Concentration (IC50)	0.07	nM	NCI-H1573 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.07	nM	LoVo cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.1	nM	EBC-1 cells	Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.1	nM	BT-20 cells	Invasive breast carcinoma of no special type
Half Maximal Inhibitory Concentration (IC50)	0.1	nM	A-549 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.1	nM	T84 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.17	nM	SK-MES-1 cells	Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.2	nM	U-118MG cells	Astrocytoma
Half Maximal Inhibitory Concentration (IC50)	0.21	nM	U-87MG cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	0.4	nM	NCI-H1650 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.7	nM	NCI-H1703 cells	Lung squamous cell carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.97	nM	CHLA-03-AA cells	Anaplastic astrocytoma
Half Maximal Inhibitory Concentration (IC50)	2.45	nM	PFSK-1 cells	Primitive neuroectodermal tumor
Half Maximal Inhibitory Concentration (IC50)	26	nM	SW480 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	28.2	nM	SNB-75 cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	> 67	nM	Caco-2 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 67	nM	HCT 15 cells	Colon adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	> 67	nM	A-172 cells	Glioblastoma
Half Maximal Inhibitory Concentration (IC50)	141	nM	T98G cells	Glioblastoma

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	70.68% (Day 36)	Low MET expression (MET+; IHC 1+)
Method Description	Tumor fragments of 3 to 5 mm at passage 3 were implanted subcutaneously in the right rear flank of NSG mice with a trochar. ABT-700 PBD was administered 0.3 mg/kg every seven days for a total of six doses.
In Vivo Model	Non-small cell lung cancer PDX model (PDX: CTG-0363)
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	75.79% (Day 22)	High MET expression (MET+++; IHC 3+)
Method Description	Tumor fragments of 3 to 5 mm at passage 3 were implanted subcutaneously in the right rear flank of NSG mice with a trochar. ABT-700 PBD was administered 0.3 mg/kg every seven days for a total of six doses.
In Vivo Model	Non-small cell lung cancer PDX model (PDX: CTG-0170)
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	88.94% (Day 21)	Moderate MET expression (MET++; IHC 2+)
Method Description	Tumor fragments of 3 to 5 mm at passage 3 were implanted subcutaneously in the right rear flank of NSG mice with a trochar. ABT-700 PBD was administered 0.3 mg/kg every seven days for a total of six doses.
In Vivo Model	Non-small cell lung cancer PDX model (PDX: CTG-0159)

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	92.94% (Day 32)	Positive MET expression (MET +++/++)
Method Description	Mice were randomized when the tumors reached -200 mm and dosed on day 0 with isotype or ADC at 0.3 mg/kg intraperitoneally.
In Vivo Model	SW48 CDX model
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	SK-CO-1 cells		CVCL_0626
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	LS174T cells		CVCL_1384
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 1.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Astrocytoma	U-138MG cells		CVCL_0020
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 1.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	M059J cells		CVCL_0400
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 1.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	M059K cells		CVCL_0401
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 1.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Anaplastic astrocytoma	DBTRG-05MG cells		CVCL_1169
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.90 pM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	SW48 cells		CVCL_1724
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung squamous cell carcinoma	HCC15 cells		CVCL_2057
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	DLD-1 cells		CVCL_0248
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	HT-29 cells		CVCL_0320
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon carcinoma	HCT 116 cells		CVCL_0291
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	SW620 cells		CVCL_0547
Experiment 13 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Gliosarcoma	SF264 cells		Homo sapiens
Experiment 14 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	SW403 cells		CVCL_0545
Experiment 15 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Astrocytoma	SNB-19 cells		CVCL_0535
Experiment 16 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	COLO 201 cells		CVCL_1987
Experiment 17 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	< 7.00 pM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Astrocytoma	U-251MG cells		CVCL_0021
Experiment 18 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	High MET expression (MET+++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung papillary adenocarcinoma	NCI-H441 cells		CVCL_1561
Experiment 19 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon carcinoma	RKO cells		CVCL_0504
Experiment 20 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Rectal adenocarcinoma	SW1463 cells		CVCL_1718
Experiment 21 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.01 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	WiDr cells		CVCL_2760
Experiment 22 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	High MET expression (MET+++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Gastric adenocarcinoma	Hs 746.T cells		CVCL_0333
Experiment 23 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	M059J cells		CVCL_0400
Experiment 24 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Pancreatic carcinoma	KP-4 cells		CVCL_1338
Experiment 25 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung papillary adenocarcinoma	NCI-H820 cells		CVCL_1592
Experiment 26 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung squamous cell carcinoma	SW900 cells		CVCL_1731
Experiment 27 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	COLO 205 cells		CVCL_0218
Experiment 28 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.02 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	COLO 320DM cells		CVCL_0219
Experiment 29 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.03 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	SW1116 cells		CVCL_0544
Experiment 30 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Pleural epithelioid mesothelioma	NCI-H226 cells		CVCL_1544
Experiment 31 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Cecum adenocarcinoma	LS1034 cells		CVCL_1382
Experiment 32 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	COLO 320HSR cells		CVCL_0220
Experiment 33 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.04 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Gliosarcoma	SF539 cells		CVCL_1691
Experiment 34 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1573 cells		CVCL_1478
Experiment 35 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.07 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	LoVo cells		CVCL_0399
Experiment 36 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	High MET expression (MET+++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung squamous cell carcinoma	EBC-1 cells		CVCL_2891
Experiment 37 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Invasive breast carcinoma of no special type	BT-20 cells		CVCL_0178
Experiment 38 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	A-549 cells		CVCL_0023
Experiment 39 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.10 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	T84 cells		CVCL_0555
Experiment 40 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.17 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung squamous cell carcinoma	SK-MES-1 cells		CVCL_0630
Experiment 41 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.20 nM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Astrocytoma	U-118MG cells		CVCL_0633
Experiment 42 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.21 nM	Low MET expression (MET+)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	U-87MG cells		CVCL_0022
Experiment 43 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.40 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung adenocarcinoma	NCI-H1650 cells		CVCL_1483
Experiment 44 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.70 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Lung squamous cell carcinoma	NCI-H1703 cells		CVCL_1490
Experiment 45 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.97 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Anaplastic astrocytoma	CHLA-03-AA cells		CVCL_U616
Experiment 46 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2.45 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Primitive neuroectodermal tumor	PFSK-1 cells		CVCL_1642
Experiment 47 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	26.00 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	SW480 cells		CVCL_0546
Experiment 48 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28.20 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	SNB-75 cells		CVCL_1706
Experiment 49 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	Caco-2 cells		CVCL_0025
Experiment 50 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Colon adenocarcinoma	HCT 15 cells		CVCL_0292
Experiment 51 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 67.00 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	A-172 cells		CVCL_0131
Experiment 52 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	141 nM	Positive MET expression (MET +++/++)
Method Description	Cancer cell lines were incubated with compounds for 72 h. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model	Glioblastoma	T98G cells		CVCL_0556

Ref 1	ANTI-cMet antibody drug conjugates and methods for their use; 2017-11-23.